Literature DB >> 22439933

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Shizhen Zhu1, Jeong-Soo Lee, Feng Guo, Jimann Shin, Antonio R Perez-Atayde, Jeffery L Kutok, Scott J Rodig, Donna S Neuberg, Daniel Helman, Hui Feng, Rodney A Stewart, Wenchao Wang, Rani E George, John P Kanki, A Thomas Look.   

Abstract

Amplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation. We generated a transgenic zebrafish model of neuroblastoma in which MYCN-induced tumors arise from a subpopulation of neuroblasts that migrate into the adrenal medulla analog following organogenesis. Coexpression of activated ALK with MYCN in this model triples the disease penetrance and markedly accelerates tumor onset. MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differentiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoadrenal cells. Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22439933      PMCID: PMC3315700          DOI: 10.1016/j.ccr.2012.02.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  43 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

2.  The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Authors:  Takaaki Sasaki; Katsuhiro Okuda; Wei Zheng; James Butrynski; Marzia Capelletti; Liping Wang; Nathanael S Gray; Keith Wilner; James G Christensen; George Demetri; Geoffrey I Shapiro; Scott J Rodig; Michael J Eck; Pasi A Jänne
Journal:  Cancer Res       Date:  2010-10-28       Impact factor: 12.701

3.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

4.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

Authors:  Sara De Brouwer; Katleen De Preter; Candy Kumps; Piotr Zabrocki; Michaël Porcu; Ellen M Westerhout; Arjan Lakeman; Jo Vandesompele; Jasmien Hoebeeck; Tom Van Maerken; Anne De Paepe; Geneviève Laureys; Johannes H Schulte; Alexander Schramm; Caroline Van Den Broecke; Joëlle Vermeulen; Nadine Van Roy; Klaus Beiske; Marleen Renard; Rosa Noguera; Olivier Delattre; Isabelle Janoueix-Lerosey; Per Kogner; Tommy Martinsson; Akira Nakagawara; Miki Ohira; Huib Caron; Angelika Eggert; Jan Cools; Rogier Versteeg; Frank Speleman
Journal:  Clin Cancer Res       Date:  2010-08-18       Impact factor: 12.531

7.  MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

Authors:  Goleeta Alam; Hongjuan Cui; Huilin Shi; Liqun Yang; Jane Ding; Ling Mao; William A Maltese; Han-Fei Ding
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

8.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

Review 9.  Molecular pathogenesis of peripheral neuroblastic tumors.

Authors:  I Janoueix-Lerosey; G Schleiermacher; O Delattre
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

10.  Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Authors:  Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

View more
  136 in total

1.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

2.  Efficient transgenesis mediated by pigmentation rescue in zebrafish.

Authors:  Itrat Harrold; Seth Carbonneau; Bethany M Moore; Gina Nguyen; Nicole M Anderson; Amandeep S Saini; John P Kanki; Cicely A Jette; Hui Feng
Journal:  Biotechniques       Date:  2016-01-01       Impact factor: 1.993

3.  A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.

Authors:  Shinji Kohsaka; Neerav Shukla; Nabahet Ameur; Tatsuo Ito; Charlotte K Y Ng; Lu Wang; Diana Lim; Angela Marchetti; Agnes Viale; Mono Pirun; Nicholas D Socci; Li-Xuan Qin; Raf Sciot; Julia Bridge; Samuel Singer; Paul Meyers; Leonard H Wexler; Frederic G Barr; Snjezana Dogan; Jonathan A Fletcher; Jorge S Reis-Filho; Marc Ladanyi
Journal:  Nat Genet       Date:  2014-05-04       Impact factor: 38.330

4.  ALK and MYCN: when two oncogenes are better than one.

Authors:  Zhihui Liu; Carol J Thiele
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

5.  Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

Authors:  M Mohammadi; M Goodarzi; M R Jaafari; H R Mirzaei; H Mirzaei
Journal:  Cancer Gene Ther       Date:  2016-10-14       Impact factor: 5.987

6.  Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

Authors:  Isabelle Westerlund; Yao Shi; Konstantinos Toskas; Stuart M Fell; Shuijie Li; Olga Surova; Erik Södersten; Per Kogner; Ulrika Nyman; Susanne Schlisio; Johan Holmberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

7.  LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Authors:  Shizhen Zhu; Xiaoling Zhang; Nina Weichert-Leahey; Zhiwei Dong; Cheng Zhang; Gonzalo Lopez; Ting Tao; Shuning He; Andrew C Wood; Derek Oldridge; Choong Yong Ung; Janine H van Ree; Amish Khan; Brittany M Salazar; Edroaldo Lummertz da Rocha; Mark W Zimmerman; Feng Guo; Hong Cao; Xiaonan Hou; S John Weroha; Antonio R Perez-Atayde; Donna S Neuberg; Alexander Meves; Mark A McNiven; Jan M van Deursen; Hu Li; John M Maris; A Thomas Look
Journal:  Cancer Cell       Date:  2017-08-31       Impact factor: 31.743

8.  Features of the structure, development, and activity of the zebrafish noradrenergic system explored in new CRISPR transgenic lines.

Authors:  Matthew J Farrar; Kristine E Kolkman; Joseph R Fetcho
Journal:  J Comp Neurol       Date:  2018-10-15       Impact factor: 3.215

9.  The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.

Authors:  Bin Yi; Jixin Yang; Lizhong Wang
Journal:  Tumour Biol       Date:  2013-11-30

Review 10.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.